rs16861194 — ADIPOQ -11426A>G

Upstream promoter variant that reduces ADIPOQ transcription, lowering circulating adiponectin and increasing risk of type 2 diabetes under additive and dominant models

See your personal result for ADIPOQ

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ADIPOQ -11426A>G — When the Adiponectin Thermostat Is Set Too Low

Adiponectin is often called the body's metabolic thermostat. Secreted exclusively by fat tissue, it circulates in the bloodstream and signals the liver and muscles to take up glucose, burn fatty acids, and remain sensitive to insulin. Low adiponectin is one of the most consistent laboratory findings in people with type 2 diabetes, metabolic syndrome, and cardiovascular disease. The rs16861194 variant sits just upstream of the ADIPOQ gene and acts like a dimmer on the gene's promoter — the G allele appears to turn the dial down.

The Mechanism

rs16861194 is located approximately 11,426 base pairs upstream of the ADIPOQ transcription start site11 transcription start site
the position in DNA where RNA copying begins, placing it in the gene's promoter region — the regulatory DNA that determines how actively the gene is transcribed. The A-to-G substitution is predicted to alter transcription factor binding affinity at this promoter site, reducing ADIPOQ expression in adipocytes. Lower ADIPOQ transcription means less adiponectin protein secreted into the bloodstream. With less adiponectin available, the liver and skeletal muscle receive a weaker signal to clear glucose from the blood and oxidise fatty acids, progressively worsening insulin sensitivity over time. This upstream promoter mechanism contrasts with coding variants (like rs2241766) that alter the adiponectin protein itself; here, the protein is structurally normal but produced in smaller amounts.

The Evidence

The strongest single-study evidence comes from Wang et al. (2009), who genotyped 11 ADIPOQ-pathway variants in 985 type 2 diabetes cases and 1,050 controls in Han Chinese22 985 type 2 diabetes cases and 1,050 controls in Han Chinese
Wang et al. Association study of the single nucleotide polymorphisms in adiponectin-associated genes with type 2 diabetes in Han Chinese. J Genet Genomics, 2009. Of all variants tested, rs16861194 was the only one reaching significance: OR=1.29 (95%CI 1.08–1.55, P=0.007). The finding was subsequently replicated in a Tunisian Arab cohort of 917 T2DM cases and 748 controls33 917 T2DM cases and 748 controls
Mtiraoui et al. ADIPOQ SNPs and haplotypes contribute to T2DM genetic risk in Tunisian Arabs. Diabetes Res Clin Pract, 2012, where the G allele was significantly overrepresented in cases (P<0.001) under both additive and dominant models. A meta-analysis of 8 independent studies44 meta-analysis of 8 independent studies
Chu et al. AdipoQ polymorphisms are associated with T2DM: a meta-analysis study. Diabetes Metab Res Rev, 2013 pooled the evidence and found an OR of 1.15 (95%CI 1.04–1.27) under the additive model, with the effect most pronounced in European populations. A separate study reported that rs16861194 also associates with the systolic blood pressure response to potassium supplementation (P=0.026), suggesting its reach extends to cardiovascular-related metabolic regulation beyond glucose alone. Notably, one Chinese study found no direct relationship between rs16861194 and plasma adiponectin concentration despite hypertension associations, raising the possibility that this promoter variant's primary effect may operate through tissue-level signalling rather than simply circulating adiponectin quantity.

The overall evidence picture is moderate: the T2DM association is replicated across multiple independent populations and a meta-analysis, but effect sizes are small (OR ~1.15–1.29), not all studies find an effect, and the functional mechanism at the promoter level has not been confirmed by in-vitro reporter assays specifically for this variant.

Practical Actions

Carriers of one or two G alleles face a modestly elevated metabolic risk that responds well to evidence-based strategies targeting insulin sensitivity and glucose regulation. Monitoring fasting glucose and insulin at regular intervals provides early warning of deteriorating metabolic health. Dietary patterns that specifically raise adiponectin levels — particularly higher intake of long-chain omega-3 fatty acids (EPA and DHA from fish or algae) and magnesium-rich whole foods — are mechanistically relevant: both nutrients are documented to increase adiponectin secretion from adipose tissue. Reducing visceral adiposity is the most powerful lever for raising adiponectin, because adiponectin output per adipocyte falls sharply as cells enlarge with excess fat.

Interactions

rs16861194 sits in a haplotype block (Block 1) that includes rs4632532 and rs266729. Studies consistently analyse these as a haplotype unit, and the T2DM risk appears to be partly driven by haplotype combinations rather than rs16861194 alone. The related ADIPOQ coding variant rs2241766 (G276T) affects adiponectin protein structure and circulating levels through a different mechanism; carrying risk alleles at both loci may compound the reduction in adiponectin function. CDH13 rs4783244, which encodes the adiponectin receptor cadherin-13, is a pathway partner — impaired adiponectin signalling from reduced production (rs16861194) combined with impaired receptor-mediated uptake (rs4783244) represents a double hit on the adiponectin–insulin-sensitivity axis. Interaction with dietary potassium intake (documented effect on blood pressure response, P=0.026) suggests that potassium status may modulate the cardiovascular dimension of this variant's impact.

Nutrient Interactions

adiponectin (endogenous) altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal Producer Normal

Normal ADIPOQ promoter activity — no genetically elevated T2DM risk

The A/A genotype at rs16861194 represents the wild-type promoter configuration, where transcription factor binding at the -11426 site proceeds without disruption. Normal ADIPOQ expression supports adequate adiponectin secretion from adipose tissue, which in turn maintains insulin sensitivity in the liver and skeletal muscle. Large meta-analyses using this genotype as the reference group find no elevated type 2 diabetes risk. Your adiponectin levels are primarily governed by other factors: body composition (visceral fat strongly suppresses adiponectin), sex (women have ~20-40% higher levels than men), exercise, and dietary factors including omega-3 fat intake.

AG Reduced Producer Intermediate

One copy of the promoter risk allele — modest elevation in type 2 diabetes risk

The AG heterozygote state places the rs16861194 risk allele in a single-copy context. The dominant and additive genetic models both show significant T2DM association in the literature, meaning that one G allele is sufficient to confer a measurable effect — you don't need two copies. The OR of 1.15–1.29 translates to a modest but real shift in baseline metabolic risk that interacts with lifestyle and dietary factors. Importantly, adiponectin levels are also strongly influenced by visceral fat accumulation: if abdominal fat is low, the promoter effect may be largely overcome by the body's normal adiponectin secretion. Conversely, if visceral fat is elevated, this promoter variant compounds the suppression. Monitoring fasting insulin and fasting glucose annually is a reasonable approach to catching early deterioration.

GG Low Producer Reduced

Two copies of the promoter risk allele — elevated type 2 diabetes risk

The GG homozygote represents the maximum promoter-suppression state for this locus. With both alleles carrying the transcription-disrupting G substitution, ADIPOQ expression is expected to be reduced bilaterally. Lower adiponectin output impairs insulin sensitisation in skeletal muscle and liver, and reduces the anti-inflammatory and anti-atherogenic signalling that adiponectin provides to the vascular endothelium. Clinically this manifests as increased baseline risk of insulin resistance, type 2 diabetes, and potentially hypertension and metabolic syndrome. The GG genotype is rare enough that most studies lack power to estimate its OR precisely relative to AA; the meta-analytic effect size (OR ~1.15 per allele) implies an approximate GG vs AA OR of ~1.30–1.45 under the additive assumption. Regular metabolic monitoring and proactive management of visceral adiposity and omega-3/magnesium status are especially important at this genotype level.